Back to Condition
CLN10 disease
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

CLN10 Disease

CLN10 disease is an extremely rare and devastating genetic neurodegenerative condition belonging to the neuronal ceroid lipofuscinoses, leading to severe brain cell loss and early mortality.

Overview

CLN10 disease is a severe form of neuronal ceroid lipofuscinosis (NCL), a group of disorders characterized by progressive decline in vision, motor function, and intellectual capability due to nervous system degeneration. NCL disorders are categorized by their specific genetic causes, with "CLN" designating neuronal ceroid lipofuscinosis followed by a subtype number.

Signs and Symptoms

The manifestations of CLN10 disease vary depending on the age of onset:

Congenital/Infantile Onset

Most frequently, CLN10 disease manifests immediately at birth or shortly thereafter, with indications that seizures may begin prenatally in the womb. Symptoms include:

  • Severe muscle rigidity
  • Respiratory failure
  • Status epilepticus: Prolonged episodes of seizure activity lasting several minutes
  • Marked microcephaly, with brains measuring less than half of normal volume
  • Severe loss of brain cells within the cerebellum (responsible for coordinating movement) and the cerebral cortex (responsible for cognition and emotion)
  • Severe deficiency in myelin, the protective fatty coating around nerve fibers

Infants with this severe congenital form typically survive only hours to weeks after delivery.

Late-Onset Form

Less commonly, symptoms do not appear until later, emerging between late infancy and adulthood. Manifestations develop progressively and include:

  • Loss of balance and motor coordination (ataxia)
  • Loss of speech
  • Progressive intellectual and cognitive decline
  • Vision loss

Individuals with late-onset CLN10 disease experience a shortened lifespan, determined largely by the age at which symptoms first manifest.

Causes

CLN10 disease is caused by mutations in the CTSD gene, which provides instructions for synthesizing an enzyme called cathepsin D. Cathepsin D functions within lysosomes—cellular compartments responsible for breaking down and recycling molecules—where it cuts apart specific proteins to degrade them, activate target molecules, or regulate cellular death.

  • Congenital cases: Severe mutations cause a total absence of cathepsin D enzyme activity. Undigested proteins and fats accumulate abnormally within lysosomes, severely damaging nerve cells and leading to rapid neurological decline before or shortly after birth.
  • Later-onset cases: Mutations allow partial enzyme function. Because some proteins and fats continue to be broken down, toxic lysosomal buildup progresses more slowly, delaying the onset of symptoms.

Inheritance

CLN10 disease is inherited in an autosomal recessive pattern. An individual must inherit two mutated copies of the CTSD gene (one from each parent) to be affected. Carrier parents holding one mutated copy typically show no symptoms of the disorder.

Frequency

The precise prevalence of CLN10 disease is unknown, though it is exceptionally rare, with at least 11 cases recorded in the medical literature.

Other Names

  • Cathepsin D deficiency
  • Cathepsin D deficient neuronal ceroid lipofuscinosis
  • CLN10
  • Congenital neuronal ceroid lipofuscinosis
  • Neuronal ceroid lipofuscinosis 10
  • Neuronal ceroid lipofuscinosis due to cathepsin D deficiency

Frequently Asked Questions

The first clues can appear in utero or immediately after birth, such as abnormal fetal movements, seizures that begin before delivery, or a sudden onset of severe muscle stiffness. Newborns may also show respiratory distress, microcephaly (a noticeably small head), and a lack of spontaneous eye movements. If any of these signs are observed, a prompt referral to a pediatric neurologist and geneticist is essential for early evaluation.
Currently, there is no cure, but experimental therapies are in development. Supportive care focuses on managing seizures with antiepileptic drugs, providing respiratory support, and using physical therapy to maintain muscle tone. Gene therapy trials targeting the CTSD gene are underway in research settings, but they are not yet available as standard care.
Life expectancy is closely tied to the age of symptom onset. In the severe congenital form, affected infants often survive only hours to weeks after birth. In the milder late‑onset form, individuals may live into their teens or early twenties, but the disease typically leads to progressive loss of motor and cognitive functions, culminating in respiratory failure. Early palliative care discussions are recommended to address quality‑of‑life concerns.===
Confirmation requires a combination of clinical assessment, neuroimaging, and laboratory studies. A brain MRI may show reduced brain volume and cerebellar atrophy. The definitive diagnosis is made by sequencing the CTSD gene to identify pathogenic mutations. A DNA test from a blood sample is the standard approach, and if a mutation is found, family members can be offered carrier testing.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab